Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Gilead Sciences' chief medical officer ... Gilead's chief executive, Daniel O'Day, said that Parsey had made "significant contributions" as CMO over the last five years, which were "pivotal ...

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences ... chief executive Daniel O'Day's strategy of ...

Though it is unclear how much of this vitriolic backlash will continue in the future, leaders from the pharma, biotech and life sciences industries will ... in its 2025 primary peer group. Gilead paid ...

Elsewhere, Gilead CEO Daniel O’Day hired Berger away from Sanofi. Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development ...

Shares of Gilead Sciences Inc. GILD advanced 1.08% to $107.89 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.16% to ...

"Stigma isn't just a social issue; it's a public health crisis." says Marcus Wilson, Gilead Senior Director, U.S. Public Affairs, HIV Advocacy. "It determines the quality of care that people ...

"It's time to remove the blame." Originally published by Gilead Sciences View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.